• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, September 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Targets and patented drugs for chemotherapy of Chagas disease

Bioengineer by Bioengineer
January 17, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Chagas diseaseis a parasitic infection typically spread by triatomine vectors, affecting millions of people all over Latin America. Existing chemotherapy is centered on benznidazole and nifurtimox, providing unsatisfactory results and substantial side effects. The transmission of the disease by people migration has determined the emergence as a public health problem elsewhere in non-endemic countries of the word.So, the finding of novel ways to challenge this neglected disease is a main priority. Progress in scientific knowledge about Trypanosoma cruzi in the period comprising last 15-years has increased the identification of multiple targets for Chagas“ disease chemotherapy. Ergosterol biosynthesis pathway and cruzipain, the key cysteine protease (CP) of T.cruzi, considered as the best encouraging targets for trypanocidal drugs. Recent unfortunate clinical trials investigating the administration of pozoconazole and ravuconazole to chronic patients; an approach for the fast development of novel anti-T.cruzi chemotherapy focused on the CP inhibitor K777, which is close to entering the clinical trial phase. The combination of known drugs with existing trypanocidal agents and compounds recently identified as clinical candidates for Chagas disease can be considered among the finest points of the manuscript. In addition, trypanothione biosynthesis, thiol-dependant redox and polyamine metabolism, the glycolytic, glyconeogenic, pentose phosphate, lipidic and polyisoprenoid biosynthetic pathways, and specific enzymes from these biosynthetic pathways have been also specifically discussed. Novel synthesized anti-T. cruzi compounds with or without specific single or multi-target assigned have been also described in detail. In summary, loans on anti-Chagas disease agents focused to specific parasite targets as their metabolic pathways or specific enzymes have been summarized. Patent literature collected and published from 2000 to 2015, alleging inhibitors for specific T. cruzi targets or trypanocidal activity was achieved over the search database from Delphion Research intellectual property network including international patents and the European patent office, Espacenet.

###

For more information about the article, please visit https://benthamscience.com/journals/recent-patents-on-anti-infective-drug-discovery/volume/11/issue/2/page/74/

Reference: Duschak, VG.; (2016). Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period. Recent Patents on Anticancer Drug Discovery, DOI: 10.2174/1574891X11666161024165304

Media Contact

Faizan ul Haq
[email protected]
@BenthamScienceP

http://benthamscience.com/

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Revolutionizing Art Education with Multimodal Deep Learning

September 3, 2025

KIF13B Protein Regulates Liver Metabolism, Combats Fatty Liver

September 3, 2025

Transforming Date Palm Waste into Probiotic Yogurt Enhancements

September 3, 2025

Tech-Enhanced Nursing Strategies Boost TB Medication Adherence

September 3, 2025
Please login to join discussion

POPULAR NEWS

  • Needlestick Injury Rates in Nurses and Students in Pakistan

    296 shares
    Share 118 Tweet 74
  • Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    154 shares
    Share 62 Tweet 39
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    143 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    117 shares
    Share 47 Tweet 29

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Revolutionizing Art Education with Multimodal Deep Learning

KIF13B Protein Regulates Liver Metabolism, Combats Fatty Liver

Transforming Date Palm Waste into Probiotic Yogurt Enhancements

  • Contact Us

Bioengineer.org Ā© Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org Ā© Copyright 2023 All Rights Reserved.